about
Weekly verification of dosimetric data for virtual wedge using a 2D diode detector array.Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinomaVolumetric PET/CT parameters predict local response of head and neck squamous cell carcinoma to chemoradiotherapyEfficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.Definitive radiotherapy for primary vaginal cancer: correlation between treatment patterns and recurrence rateEstimation of the total rectal dose of radical external beam and intracavitary radiotherapy for uterine cervical cancer using the deformable image registration method.A surveillance study of intensity-modulated radiation therapy for postoperative cervical cancer in JapanIntensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume hTreatment outcomes using CyberKnife for brain metastases from lung cancer.Correlation between patients' anatomical characteristics and interfractional internal prostate motion during intensity modulated radiation therapy for prostate cancer.Patterns of radiotherapy practice for biliary tract cancer in Japan: results of the Japanese radiation oncology study group (JROSG) survey.Feasibility and accuracy of relative electron density determined by virtual monochromatic CT value subtraction at two different energies using the gemstone spectral imagingChemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patientsCharacterization of in vitro radiosensitization in mammalian cells using biomathematical modelling: implications for hypofractionated radiotherapy with a combined modality approachEstimation of rectal dose using daily megavoltage cone-beam computed tomography and deformable image registration.Proposed definition of the vaginal cuff and paracolpium clinical target volume in postoperative uterine cervical cancer.A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes.Factors influencing survival outcome for radiotherapy for biliary tract cancer: a multicenter retrospective study.A case of bullous pemphigoid exacerbated by irradiation after breast conservative radiotherapy.A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes.Insulin-like growth factor stimulation increases radiosensitivity of a pancreatic cancer cell line through endoplasmic reticulum stress under hypoxic conditions.Predictors of Survival in Patients With FIGO Stage IVB Cervical Cancer.Prognostic Significance of Pretreatment Thrombocytosis in Cervical Cancer Patients Treated With Definitive Radiotherapy.Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).Curtailing patient-specific IMRT QA procedures from 2D dose error distribution.Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.Characteristics of flattening filter free beams at low monitor unit settings.Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone.Rectal dose and source strength of the high-dose-rate iridium-192 both affect late rectal bleeding after intracavitary radiation therapy for uterine cervical carcinoma.Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors.A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.Reirradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer: a single institutional experience.Suppression of PI3K/mTOR pathway rescues LLC cells from cell death induced by hypoxia.Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy.What is the optimum minimum segment size used in step and shoot IMRT for prostate cancer?Novel Radiobiological Gamma Index for Evaluation of 3-Dimensional Predicted Dose Distribution.Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients.The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy.High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma.
P50
Q33600665-C6295998-0DFE-4EF0-BB1A-A464817DF1C0Q34320528-01A18158-3606-438D-A21F-D814486D68A6Q34998582-6B662E51-C949-4644-9B25-765651F0F2C6Q35234030-2C4428D5-DF0F-459C-B24F-03CACE398B76Q35234055-EEEBC0BA-14D2-48E7-AA46-EFBB8D3C93BAQ35591805-E05D5178-1222-460F-93D1-D63F20B39F3DQ35835126-5A660003-0662-4435-91C3-D4CFC774BE36Q36010000-C874B76F-8F7A-414B-B660-7259350F137BQ36066985-DD96EFF4-EE5A-42BC-A3E5-C93B5A5F0B77Q36234065-1CF2F7A3-2B15-42A3-8BFF-0328768C0C4CQ36755511-AB52A233-CDED-4481-A205-9776F243404FQ36769599-6B95876F-6A2C-4000-BEF9-15576D0E8FF8Q37512346-B73D81AF-7E7C-45C5-99A7-A6D124421C08Q37601070-52B64D8C-7EF7-447B-B688-E74960E86E22Q38145897-6FA6EFB4-EB84-45FD-A0E4-E00C833FA41FQ38696673-F58E5FC1-C984-40A4-B67A-A52A474DED6FQ38907388-6D92F432-1219-4907-8C4A-0319A2C06872Q39246378-EFE0A1C3-08FD-4CA3-AF03-35BD788E9D5CQ39267240-B1CB42E2-0CCE-4338-9020-3867E328D4D9Q39388708-26A9C6B8-08A9-48B6-A44E-76C198F02A00Q39914790-E6347805-DD39-4224-95FB-F407AE2BF597Q40042202-00F8CCE5-0C74-4A83-967F-24F1A831C959Q40582044-B0803D71-D857-450D-8E15-85F1B0C67503Q41106719-7D63971A-5275-4710-842B-6D9527D9BD75Q41858225-7837048B-08BA-41DA-B340-17351965E70CQ42151129-72EF457B-0621-423B-97F3-DB8CCEB939C5Q42632358-2A0FF882-646E-4A09-9271-AEFFC5E1FE2CQ43196115-F141E7AE-11A0-4CDF-9523-D79C32BDB201Q43259951-CE14E1EA-12D8-49CB-BDAD-CCA0C81545C3Q43270733-7043273A-51F2-46AE-8D8A-0FF0087C5385Q44038125-F8F168CE-CBB5-4F15-83B5-6170AC242978Q44154905-6945B2CC-F28A-4CE9-8413-9E6E49D86F21Q44915206-40604F6B-B527-4D2B-A30E-C15F0AEB7E1EQ46395173-93C941B0-0109-4644-8598-95472BB4C7E3Q46401235-D0ADCEF0-F946-4E3D-978B-9263D02A1E78Q47420781-AC3F4B65-87A7-4EA4-A92B-782E3CED2150Q48196220-B6833CE3-7A0B-4B20-8155-A7F7FAC47D90Q49148069-A07BE3AE-2BC2-42BC-B9EA-F3C87C9A7A38Q53134781-47A4E465-945A-40D1-98EC-5336D56F45B1Q53199814-62BFE20D-9347-4F96-ADC1-8ED63C84B182
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fumiaki Isohashi
@ast
Fumiaki Isohashi
@en
Fumiaki Isohashi
@es
Fumiaki Isohashi
@nl
Fumiaki Isohashi
@sl
type
label
Fumiaki Isohashi
@ast
Fumiaki Isohashi
@en
Fumiaki Isohashi
@es
Fumiaki Isohashi
@nl
Fumiaki Isohashi
@sl
prefLabel
Fumiaki Isohashi
@ast
Fumiaki Isohashi
@en
Fumiaki Isohashi
@es
Fumiaki Isohashi
@nl
Fumiaki Isohashi
@sl
P106
P1153
9842195400
P21
P31
P496
0000-0001-6342-4693